Edition:
India

Deinove SA (ALDEI.PA)

ALDEI.PA on Paris Stock Exchange

0.80EUR
13 Sep 2019
Change (% chg)

€0.01 (+1.27%)
Prev Close
€0.79
Open
€0.78
Day's High
€0.83
Day's Low
€0.77
Volume
22,868
Avg. Vol
57,358
52-wk High
€2.74
52-wk Low
€0.74

Latest Key Developments (Source: Significant Developments)

Deinove And Avril Complete Development Of Natural Feed Additive
Tuesday, 11 Jun 2019 

June 11 (Reuters) - DEINOVE SA ::DEINOVE AND AVRIL COMPLETING DEVELOPMENT OF A NATURAL FEED ADDITIVE.TWO PARTNERS AIM TO BRING A FIRST INGREDIENT TO MARKET BY END OF 2020.TESTS AIMED AT VALIDATING DOSAGE REQUIRED HAVE CONFIRMED A VERY GOOD EFFICACY OF INGREDIENT.TEAMS ARE WORKING TO DEVELOP A FORMULATION THAT MEETS REGULATORY AND INDUSTRIAL REQUIREMENTS FOR BRINGING A COMMERCIAL INGREDIENT TO MARKET.  Full Article

Deinove & Dow Sign A Collaboration Agreement
Wednesday, 5 Jun 2019 

June 5 (Reuters) - DEINOVE SA ::DEINOVE & DOW SIGN A COLLABORATION AGREEMENT FOR THE DEVELOPMENT OF A NEW COSMETIC ACTIVE INGREDIENT.COMMERCIALIZATION IS PLANNED FOR EARLY 2021.DOW SELECTED EXTRACT BELONGING TO DEINOVE PROPRIETARY STRAINS' BANK TO LAUNCH NEW COSMETIC ACTIVE INGREDIENT FOR SKIN CARE APPLICATIONS.  Full Article

US Department of Defense and Deinove Announce DNV3681 Results
Monday, 20 May 2019 

May 20 (Reuters) - DEINOVE SA ::DNV3681 DEMONSTRATED A SUPERIOR IN VITRO EFFICACY COMPARED TO CIPROFLOXACIN WHICH IS PRODUCT OF REFERENCE WHEN EXPOSED TO BACILLUS ANTHRACIS.DNV3681 IS ACTIVE MOLECULE OF DNV3837, DEVELOPED IN PARALLEL BY DEINOVE AS A POTENTIAL TREATMENT FOR GASTROINTESTINAL INFECTIONS CAUSED BY CLOSTRIDIUM DIFFICILE.  Full Article

Deinove FY Consolidated Group Loss Widens To 8.7 Million Euros
Friday, 29 Mar 2019 

March 28 (Reuters) - DEINOVE SA ::FY CONSOLIDATED GROUP LOSS EUR 8.7 MILLION VERSUS LOSS OF EUR 7.3 MILLION YEAR AGO.FY OPERATING LOSS EUR 10.5 MILLION VERSUS LOSS OF EUR 9.7 MILLION YEAR AGO.FY OPERATING REVENUE EUR 0.8 MILLION VERSUS EUR 0.2 MILLION YEAR AGO.  Full Article

Deinove Prepares Phase II For DNV3837 In Clostridium Difficile Infections
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - DEINOVE SA ::DEINOVE IS PREPARING INITIATION OF PHASE II FOR DNV3837 IN CLOSTRIDIUM DIFFICILE INFECTIONS, WITH A KEY PARTNER.TRIAL IS SCHEDULED TO BEGIN MID-2019.TEST DESIGN HAS BEEN IMPROVED FOR A BETTER ASSESSMENT OF DNV3837 EFFECTIVENESS IN TREATING CLOSTRIDIUM DIFFICILE INFECTIONS,.DEINOVE HAS CHOSEN MEDPACE AS ITS CLINICAL RESEARCH ORGANIZATION (CRO)(1) TO PREPARE AND OVERSEE TRIAL.THIS WILL BE A MULTICENTER TRIAL, TAKING PLACE MOSTLY IN UNITED STATES.  Full Article

Deinove To Market 2nd Proprietary Carotenoid-Based Cosmetic Active Ingredient In 2019
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - DEINOVE SA ::DEINOVE WILL MARKET A 2ND PROPRIETARY CAROTENOID-BASED COSMETIC ACTIVE INGREDIENT IN 2019.THIS ACTIVE INGREDIENT, WHICH TARGETS A DERMOCOSMETIC INDICATION THAT IS ON RISE, WILL BE LAUNCHED IN 2019.FIRST EFFICACY TESTS CARRIED OUT IN ITS LABORATORIES HAVE BEEN PROMISING..  Full Article

Deinove Renews Its Equity Line
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - DEINOVE SA ::DEINOVE CONFIRMS ITS FINANCING OPTIONS BY RENEWING ITS EQUITY LINE.EQUITY LINE FUNDING SET UP IN DECEMBER 2014 EXPIRED.NEW EQUITY LINE, ONCE AGAIN STRUCTURED BY KEPLER CHEUVREUX, ADDS UP TO A MAXIMUM AMOUNT OF EUR 12 MILLION OVER 36 MONTHS..THIS NEW EQUITY LINE CAN BE SUSPENDED OR TERMINATED AT ANY TIME.REMAINING EUR 8 MILLION REMAIN SUBJECTED TO RESOLUTIONS THAT WILL BE PUT TO VOTE OF 2019 GENERAL MEETING..THIS RESERVE FUNDING CAPABILITY WILL REINFORCE DEINOVE'S CASH POSITION(2) AND ALLOW COMPANY TO FINANCE ITS OPERATIONS OVER NEXT TWELVE MONTHS.2,100,000 NEW SHARES ALLOWED TO BE SUBSCRIBED WITHIN SCOPE OF RESOLUTIONS PASSED BY 2018 GENERAL MEETING ADD UP TO APPROXIMATELY EUR 4 MILLION, BASED ON CURRENT STOCK PRICE.THIS NEW PROGRAM GIVES DEINOVE ADDITIONAL FINANCIAL FLEXIBILITY PARTICULARLY IN LIGHT OF UPCOMING START OF PHASE IIA CLINICAL TRIAL OF ITS ANTIBIOTIC CANDIDATE, DNV3837.  Full Article

Deinove To Collaborate With Calibr To Explore Anti-Infectious Potentials Of Its Bacterial Collection
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - DEINOVE SA ::DEINOVE TO COLLABORATE WITH CALIBR TO EXPLORE BROADLY THE ANTI-INFECTIOUS POTENTIALS OF ITS BACTERIAL COLLECTION.  Full Article

Deinove, Solvay Sign Partnership For Marketing Of Phytoene In North America And Asia
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - DEINOVE SA ::STRATEGIC PARTNERSHIP BETWEEN DEINOVE AND SOLVAY FOR THE MARKETING OF PHYTOENE IN NORTH AMERICA AND ASIA.SOLVAY NOVECARE WILL MARKET PHYTOENE AS A COSMETIC ACTIVE INGREDIENT IN NORTH AMERICA AND ASIA UNDER NAME REGEN-OPHYT.THE COLLABORATION COULD BE EXTENDED TO OTHER DEVELOPMENTS AT A LATER STAGE.THIS AGREEMENT COMPLETES PHYTOENE DISTRIBUTION STRATEGY FOR MAIN GEOGRAPHIES.  Full Article

Deinove Cash Position Of EUR 9.9 Million At June 30
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - DEINOVE SA ::DEINOVE: 2018 HALF-YEAR CONSOLIDATED RESULTS: STRENGTHENED FINANCIAL SITUATION SUBSTANTIAL PROGRESS IN BOTH AREAS OF BUSINESS.CASH POSITION: +EUR 9.9M AT JUNE 30, 2018 COMPARED TO +EUR 4.9M AT DECEMBER 31, 2017.HALF-YEAR NET LOSS OF GROUP: -EUR 3.7M VERSUS. -EUR 3.3M IN FIRST HALF OF 2017.H1 OPERATING LOSS EUR 4.4 MILLION VERSUS LOSS EUR 4.8 MILLION YEAR AGO.H1 TOTAL OPERATING REVENUES EUR 0.7 MILLION VERSUS EUR 0.1 MILLION YEAR AGO.  Full Article